Oral S-(-)-oleocanthal (OC) was validated as an effective anti-KRASG13D-mutant colorectal cancer lead, suppressing primary tumor progression and multi-organ metastasis in an orthotopic xenograft model, with gut microbiota contributing significantly to this activity as demonstrated by antibiotic depletion and fecal microbiota transplantation experiments.
Key Findings
Results
Daily oral administration of 10 mg/kg oleocanthal impressively suppressed KRASG13D-mutant CRC HCT-116-Luc progression and metastasis in an orthotopic intra-cecally xenografted nude mouse model.
The orthotopic model was used specifically because it mimics the tumor microenvironment more closely than subcutaneous xenograft models used in prior studies.
The cancer cell line used was HCT-116-Luc, which carries the KRASG13D mutation.
Daily oral 10 mg/kg dosing was found to be more effective than intraperitoneal administration given 3 times per week.
This study represents lead validation of OC anti-CRC activity in an orthotopic model, building on earlier subcutaneous xenograft studies.
Results
Oral oleocanthal administration was more effective than intraperitoneal administration at the tested dosing schedules in suppressing KRASG13D-mutant CRC progression and metastasis.
Oral dosing was administered daily at 10 mg/kg.
Intraperitoneal administration was given 3 times per week.
The superior efficacy of oral administration suggests bioavailability or route-dependent mechanisms, potentially including gut microbiota interactions.
This finding has practical implications for potential clinical translation favoring an oral administration route.
Results
Gut microbiota depletion with a broad-spectrum antibiotics cocktail partially attenuated oleocanthal's anti-CRC activity, indicating that gut microbiota contribute to OC's anticancer effects.
An oral antibiotic depletion strategy was used to assess the contribution of gut microbiota modulation to OC anti-CRC activity.
A broad-spectrum antibiotics cocktail (ABC) was administered orally to deplete gut microbiota in tumor-bearing mice.
The attenuation was described as partial, meaning OC retained some anti-CRC activity even without gut microbiota.
This finding directly implicates gut microbiota as a contributing mechanistic component of OC's anticancer activity.
Results
Fecal microbiota transplantation from oleocanthal-treated donor mice produced dramatic greater than 99% reductions in primary tumor burden and near-complete suppression of multi-organ metastatic tumor burden in recipient mice.
FMT was conducted using fresh daily oral fecal gut microbiota treatments collected from 20 mg/kg OC-dosed nude mouse donors.
Recipient mice were orthotopic HCT-116-Luc tumor-bearing nude mice subjected to gut microbiota depletion using daily oral ABC dosing for one week before FMT dosing.
Recipient mice treated with FMT from OC-treated donors exhibited 'dramatic >99% reductions in primary and near-complete suppression of multi-organ metastatic tumor burden versus FMT controls.'
The FMT experiment design included appropriate FMT control groups for comparison.
These results suggest the gut microbiota profile established by OC treatment is itself sufficient to produce dramatic anti-tumor effects.
Background
Earlier studies had identified the SMYD2-EZH2/c-MET signaling axis and gut microbiota modulation as mechanisms underlying oleocanthal's anti-CRC activity in subcutaneous xenograft models.
Prior work established OC effectiveness in CRC progression and recurrence suppression in a subcutaneous xenograft model.
The mechanistic targets identified previously included the SMYD2-EZH2/c-MET signaling axis.
The gut microbiota contribution to OC anti-CRC activity had not been previously characterized, representing a gap addressed by the current study.
S-(-)-oleocanthal is described as 'the major EVOO phenolic,' derived from extra-virgin olive oil.
Background
The Mediterranean diet, rich in extra-virgin olive oil, is associated with a lower risk of colorectal cancer, providing the epidemiological basis for investigating oleocanthal as an anti-CRC agent.
Colorectal cancer is described as 'the second most common cancer-causing death in the United States.'
S-(-)-oleocanthal is identified as the major phenolic compound in extra-virgin olive oil (EVOO).
The association between Mediterranean diet and lower CRC risk motivated investigation of EVOO's bioactive components.
KRASG13D-mutant CRC was specifically targeted as the cancer subtype studied.
What This Means
This research suggests that a natural compound called oleocanthal (OC), found in extra-virgin olive oil, can dramatically reduce the growth and spread of a specific type of colorectal cancer in mice. The study used a sophisticated animal model where human colorectal cancer cells were implanted directly into the cecum (part of the large intestine) of mice, mimicking how cancer actually grows in the human body. When mice received oleocanthal orally every day, their tumors were strongly suppressed and cancer spread to other organs was nearly eliminated — and this daily oral dosing worked better than giving the compound by injection three times a week.
A particularly striking part of the study involved the gut microbiome — the community of bacteria living in the digestive tract. When researchers wiped out the gut bacteria in mice using antibiotics, oleocanthal's anti-cancer effects were partially reduced, suggesting that beneficial changes to gut bacteria are part of how oleocanthal fights cancer. To test this further, the researchers transferred gut bacteria from oleocanthal-treated donor mice into tumor-bearing recipient mice whose own gut bacteria had been depleted. These recipient mice showed greater than 99% reductions in primary tumor size and near-complete elimination of cancer spread to multiple organs, simply from receiving the gut bacteria profile shaped by oleocanthal treatment.
This research suggests that oleocanthal works through at least two pathways: direct effects on cancer cells and indirect effects through reshaping the gut microbiome into a cancer-fighting community. The findings provide a scientific basis for why Mediterranean diets rich in olive oil may be associated with lower colorectal cancer rates, and the authors call for future clinical trials to test whether these findings translate to humans. This research was conducted in mice, and results in animal models do not always translate directly to humans.
Tarun M, Ebrahim H, El Sayed K. (2026). Lead Validation of the Olive Phenolic S-(-)-Oleocanthal for Effective Control of KRASG13D-Mutant Colorectal Cancer Progression and Metastasis.. Nutrients. https://doi.org/10.3390/nu18162623